Skip to content
Screener

Insmed INSM EPS (Basic)

EPS (Basic) at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$0.05-102%
United Therapeutics logo
United TherapeuticsUTHR
$7.82+14.0%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
-$0.38+9.5%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$1.09+195%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.62-4.7%
Savara logo
SavaraSVRA
-$0.15-25.0%

Other financials

Income statement

See full
Revenue$425.5M+296%
Gross profit$358.3M+352%
Operating income-$1.5M+99.5%
Net income-$13.2M+95.9%
EPS (diluted)-$0.06+96.5%

Balance sheet

See full
Cash & equivalents$544.8M-57.6%
Total debt$579.9M+0.8%
Total equity$757.5M-39.4%
Total assets$2.1B-15.2%

Cash flow

See full
Operating cash flow-$88.8M+56.8%
CapEx$6.3M+79.6%
Free cash flow-$95.1M+54.5%

Valuation

See full
Market cap$28.95B+37.0%
Enterprise value$28.98B+41.9%
P/S25.4×-27.6×

Profitability

See full
Gross margin83.5%+7.7pp
Operating margin-73.9%-30.6pp
Net margin-76.9%-31.8pp
FCF margin-71%-28.6pp

Returns & leverage

See full
Return on equity-87.2%-27.3pp
Debt / equity0.8×+0.3×
Current ratio3.7×-3.0×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The source filing: Insmed’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104506-26-000041
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss before income taxes(11,373)(320,443)(173,471)(576,114)
Provision for income taxes1,8691,2433,3342,155
Net loss$(13,242)$(321,686)$(176,805)$(578,269)
Basic and diluted net loss per share$(0.06)$(1.70)$(0.82)$(3.12)
Weighted average basic and diluted common shares outstanding217,352189,302216,415185,104
Net loss$(13,242)$(321,686)$(176,805)$(578,269)
Other comprehensive income (loss):
Foreign currency translation (losses) gains(2,906)2,656(3,574)4,484

Item 1C. Consolidated Financial Statements

FAQ

What is Insmed's EPS (basic)?
Insmed (INSM) reported EPS (basic) of -$0.06 in Q2 2026.
How has Insmed's EPS (basic) changed year-over-year?
Insmed's EPS (basic) increased by 96.5% year-over-year, from -$1.70 to -$0.06.
What is the long-term trend for Insmed's EPS (basic)?
Over 4 years (2021 to 2025), Insmed's EPS (basic) has grown at a 13.4% compound annual growth rate (CAGR), from -$3.87 to -$6.40.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Ask your AI about Insmed's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude